Optimization of the synthesis of BET BD2 selective inhibitor XY153

Author:

Zhu Run12,Li Junhua2ORCID,Dong Ruibo23,Hu Qingqing2,Chen Zhiming24,Chen Xiaoshan24,Zhong Zhixin24,Xiang Qiuping2,Huang Cen5,Lin Bin16,Wu Xishan2,Zhang Yan2,Zhao Linxiang1,Xu Yong1278ORCID

Affiliation:

1. Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education Shenyang Pharmaceutical University Shenyang 110016 China

2. Center for Chemical Biology and Drug Discovery, Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences No. 190 Kaiyuan Avenue Guangzhou 510530 China

3. School of Pharmaceutical Sciences Jilin University Changchun, Jilin 130021 China

4. University of Chinese Academy of Sciences Beijing 100049 China

5. Jiangsu S&T Exchange Center with Foreign Countries No. 175 Longpan Road Nanjing 210042 China

6. Wuya College of Innovation Shenyang Pharmaceutical University Shenyang 110016 P. R. China

7. China-New Zealand Joint Laboratory on Biomedicine and Health Guangzhou 510530 China

8. State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences Guangzhou 510530 China

Abstract

AbstractXY153 is a promising BET BD2 inhibitor with an IC50 value of 0.79 nM against BRD4 BD2. It shows 354‐fold selectivity over BRD4‐BD1 and 6‐fold selectivity over other BET BD2 domains. However, the reported synthesis route of XY153 and its derivatives are extremely poor‐yielding. After the synthesis of three key fragments, XY153 can only be obtained with a yield of 1.3 % in the original four‐step reaction. In this study, we reported a three‐step alternative route in the synthesis process of XY153. The reaction conditions for this route were thoroughly investigated and optimized, resulting in a significantly improved yield of 61.5 %. This efficient synthesis route establishes a robust chemical foundation for the rapid synthesis of XY153 derivatives as BET BD2 inhibitors in the near future.

Funder

National Natural Science Foundation of China

State Key Laboratory of Respiratory Disease

China Postdoctoral Science Foundation

Publisher

Wiley

Subject

Molecular Biology,Molecular Medicine,General Chemistry,Biochemistry,General Medicine,Bioengineering

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3